Analysis Tools|
Allele Symbol Allele Name Allele ID |
Msh2tm1Mak targeted mutation 1, Tak W Mak MGI:1857940 |
||||||||||||||||||||||||||||||||||||
| Summary |
8 genotypes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• impaired
|
|
• impaired
|
|
• impaired
|
|
• impaired
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• between 2 and 5 months of age, due to tumor-related illness
|
|
• increased incidence of metastasizing lymphoma, beginning ~2 months of age, incomplete penetrance
|
| N |
• no gross abnormalities were seen
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• impaired
|
|
• impaired
|
|
• impaired
|
|
• impaired
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• the 50% survival age is around 10 months
|
|
• 76.9% of mice develop tumors, including ovarian tumors (57.6%), lung adenomas (35.9%), lung adenocarcinoma (61.3%), lymphoma (26.9%)
|
 |
• in 57.6% of mice, with the earliest onset at 5 months of age
|
|
• observe in 35.9% of mice
|
|
• observe in 26.9% of mice
|
|
• 61.3% of mutants develop lung adenocarcinomas after 10.6 months of age
|
|
• observe in 35.9% of mice
|
|
• 61.3% of mutants develop lung adenocarcinomas after 10.6 months of age
|
|
|
• in 57.6% of mice, with the earliest onset at 5 months of age
|
|
|
• in 57.6% of mice, with the earliest onset at 5 months of age
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• the 50% survival age is 4.3 months and all mutants die within 10.3 months
|
|
• 86.7% of mice develop tumors, predominantly lymphoma (76.7%) with some incidence of lung adenoma (10%)
|
|
• observe in 10% of mice
|
|
• observe in 76.7% of mice
|
|
• observe in 10% of mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mutants exhibit enhanced polyp number in the small intestine, but not in the colon compared to double ApcMin Msh2tm1Mak heterozygotes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mutants exhibit similar polyp formation in the small intestine and colon as mice heterozygous for ApcMin and homozygous for Msh2tm1Mak
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice become moribound and die from anemia and intestinal obstruction at a mean age of 82 days
|
|
• mice exhibit accelerated intestinal tumorigenesis compared to single ApcMin heterozygous mice, with a large increase in number of small and large bowel adenomas that develop
• an average of 333 adenomas are seen in 10 mutants at 47-78 days of age compared to a mean of 48 adenomas in single ApcMin heterozygotes
|
|
• mice exhibit accelerated intestinal tumorigenesis compared to single ApcMin heterozygous mice, with a large increase in number of small and large bowel adenomas that develop
• an average of 333 adenomas are seen in 10 mutants at 47-78 days of age compared to a mean of 48 adenomas in single ApcMin heterozygotes
|
|
• due to tumors
|
|
• mutants exhibit enhanced polyp formation in the small intestine and colon at 6 weeks of age compared to double heterozygous mice
• treatment with the Nos2 (iNOS) inhibitor L-NIL has no effect on polyp number
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| colorectal cancer | DOID:9256 |
OMIM:114500 |
J:75393 , J:200824 | |
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 09/30/2025 MGI 6.24 |
|
|
|
||
